Tesamorelin vs CJC-1295: Mechanism and Dosing Compared

Tesamorelin and CJC-1295 both come up in research discussions about growth hormone-releasing hormone (GHRH) analogs, and it's easy to assume that because they act on the same receptor, they're interchangeable. They aren't — one has an FDA-approved formulation, the other doesn't, and the molecules themselves are built differently. This reference lines up what's different between tesamorelin and CJC-1295 and what stays the same in the reconstitution math. It is written for research and educational purposes only and is not medical advice.

What separates tesamorelin and CJC-1295

Both peptides work through the same receptor pathway. Tesamorelin is a stabilized analog of the full 44-amino acid GHRH molecule. CJC-1295 is a modified analog of a shorter GHRH fragment, amino acids 1-29, sometimes labeled Mod GRF 1-29. Both are designed to resist the rapid breakdown that limits how long natural GHRH stays active, but they arrive at that stability through different structural modifications, which is part of why they aren't dosed or discussed identically in the research literature. Reconstitution and storage handling — swabbing the stopper, adding water slowly, swirling rather than shaking — are the same for both, since both arrive as lyophilized powder that behaves the same way in solution regardless of which GHRH fragment it's built from.

CJC-1295 also comes in two forms that matter for how it's compared to tesamorelin. CJC-1295 with DAC (Drug Affinity Complex) is modified to extend how long it stays active. CJC-1295 without DAC clears much faster and is dosed more frequently in research protocols as a result. Tesamorelin does not have a DAC variant — it is a single, defined molecule with its own approved dosing schedule for its cleared indication. Confirm which CJC-1295 form is on a given label before comparing it to a tesamorelin protocol; the two forms don't behave the same way.

Regulatory and research status

This is the sharpest difference between the two. Tesamorelin has an FDA-approved pharmaceutical formulation — marketed as Egrifta and Egrifta SV — indicated for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. That approval reflects completed human trials for that specific indication, and its labeling is publicly available through DailyMed. CJC-1295 has no FDA-approved formulation for any indication and remains a research compound studied in preclinical and limited early human research.

That distinction matters for how each is discussed, but it doesn't mean CJC-1295 is untested or tesamorelin's approval extends beyond its cleared use. Tesamorelin's approval is specific to one indication; outside that context, it is discussed here strictly as research chemistry, not as something to take. Neither compound is covered in this article as a use recommendation.

Vial formats and typical concentrations

Both peptides reach researchers as lyophilized powder in single-peptide vials, most often at these reference points:

Peptide	Common vial size	Reference water volume	Concentration
Tesamorelin	10 mg	1 mL	10 mg/mL
CJC-1295	2 mg	2 mL	1 mg/mL

These reference points are common because they land typical research doses on clean syringe marks, not because the arithmetic requires them. The peptide calculator recalculates concentration and units for any vial size and water volume you enter, for either compound.

Worked example: same formula, different molecules

The formula doesn't change based on which GHRH analog is in the vial: concentration equals mass divided by water volume, and syringe units equal that volume in mL multiplied by 100 on a U-100 insulin syringe.

Tesamorelin. A 10 mg vial with 1 mL of bacteriostatic water is 10 mg/mL. A 1 mg dose is 1 ÷ 10 = 0.1 mL, or 0.1 × 100 = 10 units.

CJC-1295. A 2 mg vial with 2 mL of bacteriostatic water is 1 mg/mL. A 0.1 mg dose is 0.1 ÷ 1 = 0.1 mL, or 0.1 × 100 = 10 units.

Same draw volume, same unit reading, two different molecules and two different concentrations — the arithmetic lines them up only because the numbers were chosen for the example. Change the vial size or water volume for either one and the units change independently.

Why one calculator covers both

Here's how we see it: the step where a research dose actually goes wrong isn't the injection, it's the reconstitution math. A U-100 insulin syringe reads a fixed 100 units per mL, so the mg-per-unit depends entirely on how much water went into the vial — a fact that holds whether the vial contains tesamorelin, CJC-1295 with DAC, or CJC-1295 without DAC. Get the water volume wrong and every draw after inherits the same error, regardless of which GHRH analog is involved. That's why a single calculator built on the mass-divided-by-volume formula covers both compounds without any peptide-specific adjustment. For the full mixing walkthrough, see how to reconstitute peptides.

Where the comparison breaks down

The reconstitution math is identical; the compounds and their regulatory histories are not. Tesamorelin's dosing schedule for its approved indication came out of completed human trials specific to that molecule and that use — it doesn't transfer to CJC-1295, which has no approved dosing schedule for any indication. And because tesamorelin and CJC-1295 both act on the GHRH receptor rather than separate ones, they don't have the same rationale for being combined that pairs like CJC-1295 and Ipamorelin do. Treating the two as swappable because they share a receptor, or assuming CJC-1295 inherits any part of tesamorelin's approval status, are the two most common mix-ups in how this comparison gets discussed.

Common mistakes

• Assuming CJC-1295 shares tesamorelin's FDA approval. It doesn't. Tesamorelin's approval covers one specific indication for the tesamorelin molecule; CJC-1295 has no approved formulation at all.
• Treating CJC-1295 with DAC and without DAC as identical. They aren't — the DAC modification is specifically what extends the compound's activity, and a protocol built around one form doesn't transfer to the other.
• Confusing mg and mcg. Tesamorelin and CJC-1295 doses are described in milligrams or micrograms depending on the source. 1 mg equals 1,000 mcg, and misreading one for the other produces a 1,000x error.
• Shaking the vial. Swirl gently instead — shaking can degrade the peptide.
• Reusing a water volume across vial sizes. A water volume that gives 10 mg/mL for a 10 mg tesamorelin vial gives a different concentration entirely on a 20 mg or 30 mg vial. Recalculate rather than reusing a number from memory.
• Assuming a dosing frequency from one compound applies to the other. Tesamorelin's approved dosing schedule was established for that specific molecule and indication. It says nothing about an appropriate frequency for CJC-1295, whose dosing interval depends on whether the DAC form is in the vial.

Related

For the tesamorelin-specific reconstitution walkthrough, see the tesamorelin reconstitution calculator guide. For CJC-1295 paired with Ipamorelin rather than tesamorelin, see CJC-1295 vs Ipamorelin. Or enter your own vial size, water volume, and target dose directly into the free peptide calculator to see the exact syringe units for either compound.